Homepage Top Section2

According to BlueWillow Biologics, the preclinical research shown that the company’s nasal vaccine adjuvant combined with Medigen’s S-2P spike protein enabled to significantly neutralise antibody response. The research

The interim analysis showed that BNT162b2 vaccine candidate is over 90% effective in preventing Covid-19 in participants without evidence of prior SARS-CoV-2 infection. BioNTech co-founder and CEO Ugur

CAN-COVID is a randomised, double-blind and placebo-controlled study designed to evaluate the efficacy and safety of canakinumab plus standard of care (SoC) in hospitalised patients with Covid-19 pneumonia

The EU approval of Forxiga was based on data from the international, multi-centre, parallel-group, randomised and double-blinded DAPA-HF phase III trial. AstraZeneca claims that Forxiga is the first

Based in Mumbai, IQGEN-X provides niche and complex drug development technologies for the pharmaceutical industry. IQGENX was founded in October 2016 to provide advanced research and technology for

The deal has a total enterprise value of around $368m. Based in Cambridge, Horizon Discovery offers CRISPR and RNAi reagents, cell models, cell engineering and base editing solutions

Under the deal, Cheplapharm will purchase Atacand (candesartan cilexetil) and Atacand Plus (a fixed-dose combination of candesartan cilexetil and hydrochlorothiazide), which is marketed in around 70 countries across

Under the deal, Bristol Myers Squibb and insitro will focus on the discovery and development of novel therapies to treat amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

The US government will take the delivery of bamlanivimab vials after it achieves an emergency use authorisation (EUA) from the US Food and Drug Administration (FDA), said Eli